VIMTALABS638.50

Vimta Labs Limited

· Pharma & Health
₹ CrorePeersSUVENTAKEMcap ₹1,416 Cr
Comp Set
In ₹ Crore except Per Share
Latest Annual
VIMTALABS
FY24
SUVEN
FY26
TAKE
FY26
Peer
Median
Valuation — at last close
P/E34.49×22.68×22.68× +52%
P/B4.43×16.05×7.99×12.02× -63%
EV/EBITDA16.38×-33.34×-129.54×-81.44× +120%
Market Cap₹1,416 Cr₹9,494 Cr₹248 Cr₹4,871 Cr -71%
Growth
Revenue CAGR 3Y14.74%-19.30%-34.07%-26.69% +155%
Revenue CAGR 5Y8.40%-12.00%-41.25%-26.63% +132%
Net Income CAGR 3Y24.20%
Revenue YoY (latest Q)10.09%91.02%73981.22%37036.12% -100%
Net Income YoY (latest Q)112.16%-147.71%216.76%34.52% +225%
Profitability
EBITDA Margin27.27%-3998.80%-3.53%-2001.17% +101%
Net Income Margin12.89%-3884.13%20.02%-1932.06% +101%
Return on Common Equity12.83%-46.73%35.00%-5.86% +319%
Return on Capital Employed15.20%-48.90%-6.20%-27.55% +155%
Return on Assets10.25%-44.27%29.94%-7.17% +243%
Credit & Quality
Total Debt/Equity0.06×0.00×0.00×0.00×
Interest Coverage24.79×-1838.51×-5.51×-922.01× +103%
Scale — latest FY
Revenue / Total Income₹318 Cr₹7.1 Cr₹54.2 Cr₹30.7 Cr +938%
Net Income₹41 Cr−₹276 Cr₹10.8 Cr−₹133 Cr +131%
Total Assets₹400 Cr₹624 Cr₹36.2 Cr₹330 Cr +21%
EPS₹18.51₹-12.13₹0.74₹-5.7 +425%
Book Value per Share₹144.2₹22.43₹2.1₹12.27 +1076%
◆ best value in the comp set per metric · Δ = subject vs median of the other companies.
« ‹ › »Latest: FY24 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.